drug
Sasineprocel
Phase 2updated 6mo agoby Aspen Neuroscience Inc
Phase 2community read0 votes
indications
indications
Parkinson's Disease
all catalysts(0)
nothing on the calendar yet
News(6)
- Bambusa shoots past IPO targets as Aspen trims offeringBambusa Therapeutics has upsized its IPO, selling more shares at the midpoint of its target range to gross $168.9 million for bispecific R&D. But Aspen Neuroscience underperformed expectations, hit…fiercebiotech · 18d ago
- Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson’sThe San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or even halt the neurodegenerative condition.biopharma_dive · 18d ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are each hoping to raise around $134 million from their respective IPOs.fiercebiotech · 21d ago
- Biotech notches 31 IPOs already this year, with 4 more joining queueThe sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom that saw nearly 100 public debuts…biospace · 25d ago
- Parkinson’s cell therapy developer files to go publicAspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.biopharma_dive · 1mo ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.fiercebiotech · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that